

# John L Gore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3758900/publications.pdf>

Version: 2024-02-01

254  
papers

7,794  
citations

57631

44  
h-index

62479

80  
g-index

257  
all docs

257  
docs citations

257  
times ranked

8865  
citing authors

#	ARTICLE	IF	CITATIONS
1	Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 65-68.	0.8	7
2	Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 9.e19-9.e27.	0.8	5
3	Patient and public involvement in the design and conduct of a large, pragmatic observational trial to investigate recurrent, high-risk non-muscle-invasive bladder cancer. Cancer, 2022, 128, 103-111.	2.0	9
4	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	2.0	3
5	Strategies to Optimize Nephrolithiasis Emergency Care (STONE): Prospective Evaluation of an Emergency Department Clinical Pathway. Urology, 2022, 160, 60-68.	0.5	3
6	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100858.	0.6	3
7	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000000235002.	0.2	1
8	Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer. Journal of Urology, 2022, 207, 496-497.	0.2	1
9	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. Nature Reviews Urology, 2022, 19, 263-279.	1.9	5
10	Associations of self-efficacy, social support and coping strategies with health-related quality of life after radical cystectomy for bladder cancer: A cross-sectional study. European Journal of Cancer Care, 2022, , .	0.7	2
11	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	0.9	32
12	A Patient-Centered Approach to Research Prioritization in Prostate Cancer. Journal of Urology, 2022, 208, 277-283.	0.2	2
13	Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. Journal of Urology, 2022, 207, 779-788.	0.2	29
14	Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation. European Urology Open Science, 2022, 39, 79-82.	0.2	3
15	Using a multilevel implementation strategy to facilitate the screening and treatment of tobacco use in the outpatient urology clinic: A prospective hybrid type I study. Cancer, 2022, 128, 1184-1193.	2.0	10
16	Longitudinal screening for depression and anxiety in prostate cancer (PC) and association with disease and treatment factors.. Journal of Clinical Oncology, 2022, 40, 5023-5023.	0.8	0
17	Spending and Out-of-Pocket Costs for Genital Gender-Affirming Surgery in the US. JAMA Surgery, 2022, 157, 799.	2.2	6
18	Help me figure this out: Qualitative explorations of patient experiences with cancer pathology reports. Patient Education and Counseling, 2021, 104, 40-44.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Patient empowerment through engagement in bladder cancer research. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 193.e13-193.e19.	0.8	7
20	The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer, 2021, 127, 1387-1394.	2.0	10
21	A national cross-sectional survey of financial toxicity among bladder cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 76.e1-76.e7.	0.8	17
22	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clinical Genitourinary Cancer, 2021, 19, 144-154.	0.9	13
23	Understanding the Economic Burden of Treating Low-Grade Upper Tract Urothelial Cancer in the United States. Urology Practice, 2021, 8, 1-7.	0.2	3
24	Washington State Surgeon Perspectives on Quality Measures in the Surgical Care of Stress Urinary Incontinence in Women. Urology Practice, 2021, 8, 78-81.	0.2	0
25	Association of the 2012 American Urological Association Vasectomy Guidelines with National Trends in Vasectomy Followup in the United States. Urology Practice, 2021, 8, 226-231.	0.2	1
26	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. Urology, 2021, 149, 154-160.	0.5	4
27	Well-being and Perceptions of Supportive Resources among Caregivers of Patients with Bladder Cancer. Bladder Cancer, 2021, 7, 43-52.	0.2	1
28	Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 236.e9-236.e20.	0.8	2
29	Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer. Urology Practice, 2021, 8, 348-354.	0.2	1
30	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. Journal of the National Cancer Institute, 2021, 113, 1336-1342.	3.0	22
31	COVID-19 Seminars Issue 2 “Introduction. Urologic Oncology: Seminars and Original Investigations, 2021,,.	0.8	0
32	Discharge Opioid Prescription Patterns After Kidney Cancer Surgery. Urology, 2021, 153, 228-235.	0.5	2
33	Prevalence and Correlates of Successful Smoking Cessation in Bladder Cancer Survivors. Urology, 2021, 153, 236-243.	0.5	16
34	Editorial Comment. Journal of Urology, 2021, 206, 238-238.	0.2	0
35	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e1-496.e8.	0.8	1
36	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value in Health, 2021, 24, 1111-1117.	0.1	9

#	ARTICLE	IF	CITATIONS
37	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. JCO Clinical Cancer Informatics, 2021, 5, 912-920.	1.0	0
38	A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 595-601.	0.8	1
39	High-intensity end-of-life care among Medicare beneficiaries with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 731.e17-731.e24.	0.8	3
40	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 732.e9-732.e16.	0.8	6
41	Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa098.	1.4	9
42	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	0.9	34
43	What Goes Up Must Come Down: Identifying Truth from Global Prostate Cancer Epidemiology. European Urology, 2020, 77, 53-54.	0.9	7
44	Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor. International Journal of Surgical Pathology, 2020, 28, 80-86.	0.4	13
45	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. Prostate Cancer and Prostatic Diseases, 2020, 23, 144-150.	2.0	9
46	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer and Prostatic Diseases, 2020, 23, 295-302.	2.0	30
47	High Burden of In-Person Kidney Cancer Surveillance in a Low Resource Population. Urology Practice, 2020, 7, 373-377.	0.2	0
48	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Practical Radiation Oncology, 2020, 10, e82-e90.	1.1	19
49	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. Bladder Cancer, 2020, 6, 71-81.	0.2	16
50	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. European Urology, 2020, 78, 731-742.	0.9	39
51	Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments. Female Pelvic Medicine and Reconstructive Surgery, 2020, 26, 431-436.	0.6	15
52	Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy. European Urology Open Science, 2020, 19, 27-36.	0.2	1
53	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncology, The, 2020, 21, 776-785.	5.1	82
54	Telemedicine and eConsults for Hospitalized Patients During COVID-19. Urology, 2020, 141, 12-14.	0.5	44

#	ARTICLE	IF	CITATIONS
55	Integration of Mental Health Metrics into Patient-centered Care of Urology Patients. European Urology Focus, 2020, 6, 1147-1149.	1.6	4
56	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 796.e1-796.e6.	0.8	13
57	Implementing Telemedicine in Response to the COVID-19 Pandemic. Journal of Urology, 2020, 204, 14-16.	0.2	96
58	Optimizing Outcomes in Urological Surgery: Postoperative Care. Urology Practice, 2020, 7, 521-529.	0.2	4
59	Intravesical therapy and risk of cystectomy and bladder cancer death after BCG fails.. Journal of Clinical Oncology, 2020, 38, e17026-e17026.	0.8	0
60	Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2020, 38, e17012-e17012.	0.8	0
61	Small cell bladder cancer: Treatment patterns and clinical outcomes.. Journal of Clinical Oncology, 2020, 38, e17014-e17014.	0.8	1
62	Associations between baseline body composition and cancer-specific mortality following neoadjuvant chemotherapy and radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2020, 38, e17015-e17015.	0.8	0
63	Editorial Comment. Journal of Urology, 2020, 203, 1007-1007.	0.2	0
64	Skeletal muscle index and adverse events during a bladder cancer treatment episode.. Journal of Clinical Oncology, 2020, 38, e17016-e17016.	0.8	0
65	The impact of telemedicine on patient-reported outcomes in urologic oncology.. Journal of Clinical Oncology, 2020, 38, e14154-e14154.	0.8	1
66	Patient-centered pathology reports for breast cancer care: Interim results of a randomized pilot study.. Journal of Clinical Oncology, 2020, 38, e19157-e19157.	0.8	0
67	Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.. Journal of Clinical Oncology, 2020, 38, e17033-e17033.	0.8	0
68	Impact of bladder cancer stage on work impairment and financial toxicity.. Journal of Clinical Oncology, 2020, 38, 460-460.	0.8	2
69	The impact of age on general and bladder cancer-specific quality of life among bladder cancer survivors.. Journal of Clinical Oncology, 2020, 38, 463-463.	0.8	0
70	Gender and quality of life in bladder cancer.. Journal of Clinical Oncology, 2020, 38, 464-464.	0.8	0
71	The impact of physician specialty on general and bladder cancer-specific quality of life among patients with muscle invasive bladder cancer.. Journal of Clinical Oncology, 2020, 38, 462-462.	0.8	3
72	Bladder cancer caregiver quality of life and patient cancer severity.. Journal of Clinical Oncology, 2020, 38, 456-456.	0.8	3

#	ARTICLE	IF	CITATIONS
73	Cancer stage and quality of life in bladder cancer.. Journal of Clinical Oncology, 2020, 38, 466-466.	0.8	0
74	Micropapillary urothelial carcinoma (mpUC): A comparative analysis of oncologic outcomes compared to conventional urothelial carcinoma (CUC).. Journal of Clinical Oncology, 2020, 38, 459-459.	0.8	0
75	Sarcomatoid urothelial carcinoma (SUC): A single-institution experience of oncologic outcomes and recurrence patterns.. Journal of Clinical Oncology, 2020, 38, 465-465.	0.8	1
76	Improving the impact of clinical documentation through patient-driven co-design: experiences with cancer pathology reports. BMJ Health and Care Informatics, 2020, 27, .	1.4	0
77	Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surgery, 2019, 154, e191629.	2.2	28
78	Delays in radical cystectomy for muscleâ€invasive bladder cancer. Cancer, 2019, 125, 2011-2017.	2.0	44
79	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. Bladder Cancer, 2019, 5, 289-298.	0.2	7
80	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. European Urology Oncology, 2019, 2, 119-125.	2.6	16
81	Inferring bladder cancer research prioritization from patient-generated online content. World Journal of Urology, 2019, 37, 1145-1150.	1.2	9
82	Nonmuscle Invasive Bladder Cancer Influences Physical Health Related Quality of Life and Urinary Incontinence. Urology, 2019, 125, 146-153.	0.5	11
83	Can We Prevent Bladder Cancer Recurrences?. European Urology, 2019, 75, 602-603.	0.9	2
84	Epidemiology of Renal Cell Carcinoma. European Urology, 2019, 75, 74-84.	0.9	917
85	Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 324-330.	0.8	11
86	Modeling recovery curves with application to prostatectomy. Biostatistics, 2019, 20, 549-564.	0.9	4
87	Does the Diagnosis of Bladder Cancer Lead to Higher Rates of Smoking Cessation? Findings from the Medicare Health Outcomes Survey. Journal of Urology, 2019, 202, 241-246.	0.2	13
88	Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms. Journal of Urology, 2019, 202, 585-591.	0.2	15
89	Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis. Journal of Urology, 2019, 202, 1136-1142.	0.2	20
90	Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of care (SOC) regimens.. Journal of Clinical Oncology, 2019, 37, 4532-4532.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC).. Journal of Clinical Oncology, 2019, 37, e16007-e16007.	0.8	6
92	Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2019, 37, 372-372.	0.8	1
93	Neoadjuvant chemotherapy utilization in muscle-invasive bladder cancer: Increasing yet inappropriate use?. Journal of Clinical Oncology, 2019, 37, 441-441.	0.8	0
94	Bladder Cancer Multidisciplinary Clinic (BCMC) model: Impact on imaging, pathology and treatment recommendations.. Journal of Clinical Oncology, 2019, 37, 4537-4537.	0.8	0
95	Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2019, 37, e16021-e16021.	0.8	0
96	Editorial Comment. Journal of Urology, 2019, 202, 524-524.	0.2	0
97	Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study. Journal of Urology, 2018, 200, 397-404.	0.2	21
98	The Morbidity of Ureteral Strictures in Patients with Prior Ureteroscopic Stone Surgery: Multi-Institutional Outcomes. Journal of Endourology, 2018, 32, 309-314.	1.1	41
99	Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study. Journal of Urology, 2018, 199, 1023-1031.	0.2	48
100	Disparities in Access and Regionalization of Care in Testicular Cancer. Clinical Genitourinary Cancer, 2018, 16, e785-e793.	0.9	32
101	Associations of specific postoperative complications with costs after radical cystectomy. BJU International, 2018, 121, 428-436.	1.3	30
102	Comparative effectiveness of a pilot patient-centered ultrasound report in the management of hydronephrosis. Journal of Pediatric Urology, 2018, 14, 57.e1-57.e7.	0.6	7
103	Health Related Quality of Life Following Radical Cystectomy: Comparative Analysis from the Medicare Health Outcomes Survey. Journal of Urology, 2018, 199, 669-675.	0.2	27
104	Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort. Urology, 2018, 113, 146-152.	0.5	15
105	The impact of readmission hospital on failure-to-rescue rates following major urologic cancer surgery. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 156.e1-156.e7.	0.8	2
106	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. European Urology Oncology, 2018, 1, 292-304.	2.6	54
107	Patient-Centered Outcomes in Bladder Cancer. Current Urology Reports, 2018, 19, 105.	1.0	4
108	Patient-centered prioritization of bladder cancer research. Cancer, 2018, 124, 3136-3144.	2.0	36

#	ARTICLE	IF	CITATIONS
109	PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. <i>Cancer</i> , 2018, 124, 2733-2739.	2.0	49
110	Follow-up imaging after acute evaluations for pediatric nephrolithiasis: Trends from a National database. <i>Journal of Pediatric Urology</i> , 2018, 14, 525-531.	0.6	6
111	Editorial Comment. <i>Urology</i> , 2018, 116, 74-75.	0.5	1
112	Neonatal Circumcision and Urinary Tract Infections in Infants With Hydronephrosis. <i>Pediatrics</i> , 2018, 142, .	1.0	26
113	Beyond classic risk adjustment: Socioeconomic status and hospital performance in urologic oncology surgery. <i>Cancer</i> , 2018, 124, 3372-3380.	2.0	4
114	Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 112-112.	0.8	2
115	Comparative effectiveness of a patient-centered prostate biopsy report in clinical prostate cancer practice.. <i>Journal of Clinical Oncology</i> , 2018, 36, 145-145.	0.8	1
116	Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 72-72.	0.8	0
117	Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State. <i>Journal of the American College of Surgeons</i> , 2017, 224, 270-275e1.	0.2	25
118	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. <i>Cancer</i> , 2017, 123, 2850-2859.	2.0	66
119	Use of medical expulsive therapy in children: An assessment of nationwide practice patterns and outcomes. <i>Journal of Pediatric Urology</i> , 2017, 13, 509.e1-509.e7.	0.6	14
120	Improving Quality in Renal Cell Carcinoma Care: Bridging the Gap Between Measurement and Meaning. <i>European Urology</i> , 2017, 72, 387-388.	0.9	0
121	Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2017, 197, 1189-1199.	0.2	128
122	Incorporating the Patient into Urologic Cancer Research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 546-547.	0.8	3
123	Patient-centered approaches to creating understandable health information. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 559-563.	0.8	7
124	Global Burden of Urologic Cancers, 1990-2013. <i>European Urology</i> , 2017, 71, 437-446.	0.9	248
125	Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2017, 197, 548-558.	0.2	84
126	Urinary Catheter Management for Nonurologists: A Resident Driven Educational Initiative. <i>Urology Practice</i> , 2017, 4, 85-90.	0.2	0



#	ARTICLE	IF	CITATIONS
127	Variable Resource Utilization in the Prenatal and Postnatal Management of Isolated Hydronephrosis. Urology, 2017, 108, 155-160.	0.5	6
128	Litmus test or destination systemic therapy? Trends in referral for surgery after initial systemic therapy in metastatic kidney cancer.. Journal of Clinical Oncology, 2017, 35, 502-502.	0.8	5
129	Beyond classical risk adjustment: Socioeconomic status and hospital performance in urologic oncology.. Journal of Clinical Oncology, 2017, 35, 526-526.	0.8	0
130	Association of chemotherapy regimen with venous thromboembolic risk in patients with urothelial tract cancer.. Journal of Clinical Oncology, 2017, 35, 314-314.	0.8	1
131	Nationwide disparities in testicular cancer care delivery: Racial, ethnic, and economic markers of patient vulnerability.. Journal of Clinical Oncology, 2017, 35, 421-421.	0.8	0
132	Impact of cytoreductive nephrectomy on timing of systemic therapy in metastatic kidney cancer.. Journal of Clinical Oncology, 2017, 35, 503-503.	0.8	1
133	Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study.. Journal of Clinical Oncology, 2017, 35, 24-24.	0.8	0
134	CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making.. Journal of Clinical Oncology, 2017, 35, 527-527.	0.8	0
135	Author Reply. Urology, 2016, 87, 87.	0.5	1
136	Relevance of graph literacy in the development of patient-centered communication tools. Patient Education and Counseling, 2016, 99, 448-454.	1.0	39
137	Patient-centered risk stratification of disposition outcomes following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 235.e17-235.e23.	0.8	22
138	More Is More: Disentangling the Importance of Ejaculation Frequency. European Urology, 2016, 70, 983-984.	0.9	0
139	AUA White Paper on Implementation of Shared Decision Making into Urological Practice. Urology Practice, 2016, 3, 355-363.	0.2	38
140	Prostate cancer screening: Do guidelines matter?. Cancer, 2016, 122, 3760-3761.	2.0	0
141	15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e1-530.e7.	0.8	8
142	Metastatic Renal Cell Carcinoma to the Contralateral Ureter: A Rare Phenomenon. Urology Case Reports, 2016, 4, 36-37.	0.1	2
143	Comparative Effectiveness of a Patient Centered Pathology Report for Bladder Cancer Care. Journal of Urology, 2016, 196, 1383-1389.	0.2	30
144	Treatment of muscle-invasive bladder cancer: A systematic review. Cancer, 2016, 122, 842-851.	2.0	85

#	ARTICLE	IF	CITATIONS
145	Root Causes and Modifiability of 30-Day Hospital Readmissions after Radical Cystectomy for Bladder Cancer. Journal of Urology, 2016, 195, 894-899.	0.2	24
146	National Trends in Secondary Procedures Following Pediatric Pyeloplasty. Journal of Urology, 2016, 195, 1209-1214.	0.2	29
147	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncology, 2016, 2, 890.	3.4	65
148	Design and feasibility of integrating personalized PRO dashboards into prostate cancer care. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 38-47.	2.2	52
149	Preliminary Comparative Effectiveness of Robotic Versus Open Radical Cystectomy in Elderly Patients. Journal of Endourology, 2016, 30, 212-217.	1.1	29
150	Hospital-level Variation in the Quality of Benign Inpatient Urologic Surgery. Urology, 2016, 87, 82-87.	0.5	3
151	Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients. Urology, 2016, 91, 70-76.	0.5	16
152	Creating patient engagement infrastructure in bladder cancer research prioritization.. Journal of Clinical Oncology, 2016, 34, e18168-e18168.	0.8	1
153	An update on penile cancer: Evaluating management trends and clinical outcomes using the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 492-492.	0.8	1
154	Utilization and sequencing of targeted therapy and cytoreductive nephrectomy in nonâ€œclear cell metastatic kidney cancer.. Journal of Clinical Oncology, 2016, 34, 615-615.	0.8	0
155	Comparative effectiveness of a patient centered pathology report for bladder cancer care.. Journal of Clinical Oncology, 2016, 34, 420-420.	0.8	0
156	Initial compared to deferred cytoreductive nephrectomy for metastatic kidney cancer and its association with improved survival in the targeted therapy era.. Journal of Clinical Oncology, 2016, 34, 607-607.	0.8	0
157	Travel Burden and the Direct Medical Costs of Urologic Surgery. Journal of Health Economics and Outcomes Research, 2016, 4, 47-54.	0.6	0
158	Accessing complex urologic surgery in the 21st century. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 379-382.	0.8	4
159	Metformin effects on biochemical recurrence and metabolic signaling in the prostate. Prostate, 2015, 75, 1694-1703.	1.2	10
160	Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects. Medical Care, 2015, 53, 79-86.	1.1	16
161	Underuse and underreporting of smoking cessation for smokers with a new urologic cancer diagnosis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 504.e1-504.e7.	0.8	11
162	Overuse of Antimicrobial Prophylaxis in Community Practice Urology. Journal of Urology, 2015, 193, 543-547.	0.2	44

#	ARTICLE	IF	CITATIONS
163	National Trends in Followup Imaging after Pyeloplasty in Children in the United States. Journal of Urology, 2015, 194, 777-782.	0.2	27
164	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.3	8
165	Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 505.e9-505.e13.	0.8	46
166	Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e253-e258.	0.9	13
167	Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. Urology, 2015, 86, 262-268.	0.5	31
168	High Regional Variation in Urethroplasty in the United States. Journal of Urology, 2015, 193, 179-183.	0.2	22
169	Hospital re-admission patterns and outcomes following major urologic cancer surgery.. Journal of Clinical Oncology, 2015, 33, 497-497.	0.8	1
170	Specificity of radiographic lymphadenopathy for lymph node metastasis in renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 442-442.	0.8	7
171	Twenty-year trends in survival for metastatic kidney cancer.. Journal of Clinical Oncology, 2015, 33, 454-454.	0.8	0
172	A novel tool to predict outcomes following radical cystectomy using age and co-morbidity status.. Journal of Clinical Oncology, 2015, 33, 354-354.	0.8	0
173	Need to travel for urologic care: The impact of insurance.. Journal of Clinical Oncology, 2015, 33, 396-396.	0.8	0
174	Improving the value of PSA prostate cancer screening with "smart" strategies and increased use of active surveillance.. Journal of Clinical Oncology, 2015, 33, 6616-6616.	0.8	0
175	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	1.4	41
176	Individualized Estimates of Overdiagnosis in Screen-Detected Prostate Cancer. Journal of the National Cancer Institute, 2014, 106, djt367-djt367.	3.0	47
177	Knowledge of the harms of tobacco use among patients with bladder cancer. Cancer, 2014, 120, 3914-3922.	2.0	37
178	Why Does Anyone Get Shock Wave Lithotripsy?. JAMA Surgery, 2014, 149, 654.	2.2	0
179	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	1.2	117
180	Identification of underserved areas for urologic cancer care. Cancer, 2014, 120, 1565-1571.	2.0	27

#	ARTICLE	IF	CITATIONS
181	The burden of bladder cancer care. Current Opinion in Urology, 2014, 24, 487-491.	0.9	138
182	User-centered design of quality of life reports for clinical care of patients with prostate cancer. Surgery, 2014, 155, 789-796.	1.0	43
183	Burden and timing of venothrombotic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 815-819.	0.8	12
184	Trends in Followup Imaging after Adult Pyeloplasty. Journal of Urology, 2014, 191, 1357-1362.	0.2	9
185	Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports. Human Pathology, 2014, 45, 2192-2201.	1.1	22
186	Expected population impacts of discontinued prostate-specific antigen screening. Cancer, 2014, 120, 3519-3526.	2.0	90
187	Perinephric Fat Thickness Is an Independent Predictor of Operative Complexity During Robot-Assisted Partial Nephrectomy. Journal of Endourology, 2014, 28, 587-591.	1.1	57
188	Implementation of a "real-world" learning health care system: Washington state's Comparative Effectiveness Research Translation Network (CERTAIN). Surgery, 2014, 155, 860-866.	1.0	37
189	Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer. Clinical Genitourinary Cancer, 2014, 12, 287-291.	0.9	20
190	Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2014, 12, 210-213.	0.9	9
191	Use and Outcomes of Extended Antibiotic Prophylaxis in Urological Cancer Surgery. Journal of Urology, 2014, 192, 425-429.	0.2	49
192	Comparison of Selective Parenchymal Clamping to Hilar Clamping During Robotic-assisted Laparoscopic Partial Nephrectomy. Urology, 2014, 83, 339-344.	0.5	8
193	Introduction. Surgery, 2014, 155, 731.	1.0	0
194	MP15-20 SURGICAL PATHOLOGY AND THE PATIENT: A SYSTEMATIC REVIEW EVALUATING THE PRIMARY AUDIENCE OF PATHOLOGY REPORTS. Journal of Urology, 2014, 191, .	0.2	1
195	Readability of urologic pathology reports: The need for patient-centered approaches. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1091-1094.	0.8	18
196	Risk Factors for Renal Cell Carcinoma in the VITAL Study. Journal of Urology, 2013, 190, 1657-1661.	0.2	123
197	Downstream Complications Following Urinary Diversion. Journal of Urology, 2013, 190, 916-922.	0.2	42
198	Improving bladder cancer patient care: a pharmacoeconomic perspective. Expert Review of Anticancer Therapy, 2013, 13, 661-668.	1.1	13

#	ARTICLE	IF	CITATIONS
199	The Costs of Non-Muscle Invasive Bladder Cancer. Urologic Clinics of North America, 2013, 40, 261-269.	0.8	50
200	Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial. Journal of the National Cancer Institute, 2013, 105, 546-550.	3.0	26
201	Quality of life in women undergoing urinary diversion for bladder cancer: results of a multicenter study among long-term disease-free survivors. Health and Quality of Life Outcomes, 2013, 11, 43.	1.0	66
202	Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology, 2013, 2013, 1-6.	0.6	34
203	Comparative Effectiveness of Alternative Prostate-Specific Antigen-Based Prostate Cancer Screening Strategies. Annals of Internal Medicine, 2013, 158, 145.	2.0	144
204	Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder.. Journal of Clinical Oncology, 2013, 31, 267-267.	0.8	2
205	Association of persistent, unexplained leukocytosis, a paraneoplastic syndrome, with poor prognosis in patients with urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2013, 31, 291-291.	0.8	2
206	Introduction of a tobacco-screening initiative for those at risk for bladder cancer in a high volume urology clinic.. Journal of Clinical Oncology, 2013, 31, 4540-4540.	0.8	0
207	Impact of a Bladder Cancer Diagnosis on Smoking Behavior. Journal of Clinical Oncology, 2012, 30, 1871-1878.	0.8	90
208	Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1629.	3.8	351
209	Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. Clinical Cancer Research, 2012, 18, 5471-5478.	3.2	52
210	A National Study of Trauma Level Designation and Renal Trauma Outcomes. Journal of Urology, 2012, 187, 536-541.	0.2	50
211	Editorial Comment. Journal of Urology, 2012, 187, 66-67.	0.2	0
212	The Socioeconomic Status of Donors and Recipients of Living Unrelated Renal Transplants in the United States. Journal of Urology, 2012, 187, 1760-1765.	0.2	13
213	Adoption of Laparoscopic Radical Nephrectomy in the State of Washington. Urology, 2012, 79, 326-331.	0.5	3
214	Hospital-level variation in the quality of urologic cancer surgery. Cancer, 2012, 118, 987-996.	2.0	27
215	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. Journal of Clinical Epidemiology, 2011, 64, 1412-1417.	2.4	43
216	Editorial Comment. Urology, 2011, 78, 1113-1114.	0.5	1

#	ARTICLE	IF	CITATIONS
217	Readmissions in the postoperative period following urinary diversion. World Journal of Urology, 2011, 29, 79-84.	1.2	45
218	Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World Journal of Urology, 2011, 29, 73-77.	1.2	48
219	Hospice Use and High-Intensity Care in Men Dying of Prostate Cancer. Archives of Internal Medicine, 2011, 171, 204.	4.3	66
220	Influence of Publication of US and European Prostate Cancer Screening Trials on PSA Testing Practices. Journal of the National Cancer Institute, 2011, 103, 520-523.	3.0	57
221	Urinary diversion and morbidity after radical cystectomy for bladder cancer. Cancer, 2010, 116, 331-339.	2.0	80
222	Patterns of questionable quality care in nonmuscle invasive bladder cancer. Cancer, 2010, 116, 2508-2510.	2.0	3
223	Use of Radical Cystectomy for Patients With Invasive Bladder Cancer. Journal of the National Cancer Institute, 2010, 102, 802-811.	3.0	246
224	Readability of Health Related Quality of Life Instruments in Urology. Journal of Urology, 2010, 183, 1977-1981.	0.2	26
225	Correlates of Bother Following Treatment for Clinically Localized Prostate Cancer. Journal of Urology, 2010, 184, 1309-1315.	0.2	50
226	Improved Continence in Patients With Neurogenic Sphincteric Incompetence With Combination Tubularized Posterior Urethroplasty and Fascial Wrap: The Lengthening, Narrowing and Tightening Procedure. Journal of Urology, 2010, 184, 1763-1767.	0.2	14
227	Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer. Journal of the National Cancer Institute, 2009, 101, 888-892.	3.0	132
228	Mortality increases when radical cystectomy is delayed more than 12 weeks. Cancer, 2009, 115, 988-996.	2.0	223
229	Partnership and outcomes in men with prostate cancer. Cancer, 2009, 115, 4688-4694.	2.0	23
230	Quality of care in bladder cancer: trends in urinary diversion following radical cystectomy. World Journal of Urology, 2009, 27, 45-50.	1.2	74
231	Thromboembolic Complications of Sling Surgery for Stress Urinary Incontinence Among Female Medicare Beneficiaries. Urology, 2009, 74, 1223-1226.	0.5	8
232	Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy. Health and Quality of Life Outcomes, 2009, 7, 94.	1.0	53
233	Erectile Aid Use by Men Treated for Localized Prostate Cancer. Journal of Urology, 2009, 182, 649-654.	0.2	35
234	Obesity and Renal Transplantation: Is Bariatric Surgery the Answer?. Transplantation, 2009, 87, 1115.	0.5	9

#	ARTICLE	IF	CITATIONS
235	Sexual Orientation and Testing for Prostate and Colorectal Cancers Among Men in California. Medical Care, 2008, 46, 1240-1248.	1.1	55
236	Outcomes in Men Denied Access to a California Public Assistance Program for Prostate Cancer. Public Health Reports, 2007, 122, 217-223.	1.3	12
237	Ureteral tumor thrombus from renal cell carcinoma extending into bladder. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 393-395.	0.8	18
238	Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer, 2007, 109, 2239-2247.	2.0	236
239	Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer, 2007, 110, 1493-1500.	2.0	482
240	Perineocele: Symptom complex, description of anatomic defect, and surgical technique for repair. Urology, 2006, 67, 265-268.	0.5	12
241	Case Report: Avoidance of Palpable Corporal Fibrosis Due to Priapism with Upregulators of Nitric Oxide. Journal of Sexual Medicine, 2006, 3, 173-176.	0.3	29
242	The effect of postprostatectomy external beam radiotherapy on quality of life. Cancer, 2006, 107, 281-288.	2.0	32
243	Variations in reconstruction after radical cystectomy. Cancer, 2006, 107, 729-737.	2.0	121
244	Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. Nature Reviews Urology, 2006, 3, 449-452.	1.4	1
245	Laparoscopic Versus Open Renal Procurement for Pediatric Recipients of Living Donor Renal Transplantation. American Journal of Transplantation, 2005, 5, 2514-2520.	2.6	31
246	Partnership status influences quality of life in low-income, uninsured men with prostate cancer. Cancer, 2005, 104, 191-198.	2.0	49
247	Marriage and mortality in bladder carcinoma. Cancer, 2005, 104, 1188-1194.	2.0	65
248	Initial Experience with Laparoscopically Assisted Percutaneous Cryotherapy of Renal Tumors. Journal of Endourology, 2005, 19, 480-483.	1.1	21
249	Androgen Deficiency in the Etiology and Treatment of Erectile Dysfunction. Urologic Clinics of North America, 2005, 32, 457-468.	0.8	7
250	MENTAL HEALTH OF LOW INCOME UNINSURED MEN WITH PROSTATE CANCER. Journal of Urology, 2005, 173, 1323-1326.	0.2	20
251	487: Trends in Reconstruction after Radical Cystectomy in the Medicare Population. Journal of Urology, 2005, 173, 133-134.	0.2	2
252	Laparoscopic partial nephrectomy and minimally invasive nephronsparing surgery. Current Urology Reports, 2003, 4, 13-20.	1.0	4

#	ARTICLE	IF	CITATIONS
253	OPTIMAL COMBINATIONS OF SYSTEMATIC SEXTANT AND LATERALLY DIRECTED BIOPSIES FOR THE DETECTION OF PROSTATE CANCER. Journal of Urology, 2001, , 1554-1559.	0.2	8
254	Naloxegol versus Alvimopan for Enhancing Postoperative Recovery following Radical Cystectomy for Bladder Cancer. Urology Practice, 0, , .	0.2	0